Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Fly reports that on Wednesday, investment analysts at Deutsche Bank Aktiengesellschaft increased their price objective for Moderna (NASDAQ: MRNA), moving it from $185.00 to $225.00
Moderna CEO: 400% price hike on COVID vaccine “consistent with the value” nice!
https://arstechnica.com/science/2023/01/moderna-may-match-pfizers-400-price-hike-on-covid-vaccines-report-says/
The company reiterates 2023 expected minimum COVID-19 vaccine sales of approximately $5 billion, with more contracts coming in 2023.
Moderna increased investments with around $4.5 billion in 2023, up from approximately $3.3 billion in 2022. Moderna continues to scale with 48 programs in development, including 36 in ongoing clinical studies!
Moderna Inc. said it is considering pricing its Covid-19 vaccine in a range of $110 to $130 per dose in the U.S. when it shifts from government contracting to commercial distribution of the shots.
money machine$
With 65% ownership, Moderna, Inc.- boasts of strong institutional backing "up"
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/with-65-ownership-moderna-inc-nasdaqmrna-boasts-of-strong-in
Repurchased 23 million shares (avg. price $143/share) for $3.3 billion in 2022, with $2.8 billion remaining for future repurchases from the $3.0 billion August authorization " winner"
huge: MODERNA ANNOUNCES ADVANCES ACROSS MRNA PIPELINE AND PROVIDES BUSINESS UPDATE
Company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, and is increasing R&D investment to an expected $4.5 billion for 2023
"We enter 2023 in a great position, with significant momentum across our clinical pipeline, a highly energized team and a strong balance sheet of over $18 billion of cash and cash equivalents
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Advances-Across-mRNA-Pipeline-and-Provides-Business-Update/default.aspx
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Advances-Across-mRNA-Pipeline-and-Provides-Business-Update/default.aspx
anything is possible!
Proposal 6: Amendment of the Company's Certificate of Incorporation to increase the number of authorized common shares by 500 million. dilution maybe!
yes: Moderna signs $35 million deal with cancer drug developer CytomX
MODERNA TO ACQUIRE ORICIRO GENOMICS The company is located in Tokyo, Japan
today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million.
https://investors.modernatx.com/news/news-details/2023/Moderna-to-Acquire-OriCiro-Genomics/default.aspx
$80-90 buy zone!
Moderna 2022 Shareholder Letter- Preparations are underway for multiple vaccine launches globally between 2023 and 2026. : https://www.modernatx.com/media-center/all-media/blogs/moderna-2022-shareholder-letter
MODERNA TO PROVIDE BUSINESS AND PIPELINE UPDATES AT THE 2023 J.P. MORGAN HEALTHCARE CONFERENCE
https://investors.modernatx.com/news/news-details/2023/Moderna-to-Provide-Business-and-Pipeline-Updates-at-the-2023-J.P.-Morgan-Healthcare-Conference/default.aspx
Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony
https://www.ft.com/content/218af626-243f-415d-a643-21aa7d39ccf3?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
$80-90 buy zone!
In 2023, drug companies will introduce the first vaccines for respiratory syncytial virus—known as RSV—and could roll out the first flu vaccine based on messenger RNA, or mRNA. It will also be a significant year for Covid-19 shots, which are expected to make their debut on the commercial market!!!!!!!!
India on alert for new variants as Covid wave sweeps China,
The surge could lead to nearly 1 million deaths in China,
https://edition.cnn.com/2022/12/22/india/india-ramps-up-covid-measures-amid-china-surge-intl-hnk/index.html
Covid is not over yet
bad news
$MRNA WINNER: We've finalised our partnership with moderna
to protect the UK against potential global health threats.
https://www.gov.uk/government/news/uk-cements-10-year-partnership-with-moderna-in-major-boost-for-vaccines-and-research
Moderna's vaccine facility in Britain to create over 150 new jobs!
In 2023, drug companies will introduce the first vaccines for respiratory syncytial virus, known as RSV and could roll out the first flu vaccine based on messenger RNA, ......... bright future!!!!!!!!
We’re bringing the future of mRNA to Australia with a world class local scientific and medical community:
This landmark occasion at @MonashUni in Victoria Australia captures the official groundbreaking ceremony of our new #mRNA #vaccine manufacturing facility with Michael Azrak, @TimPallas, @Mark_Butler_MP, @GardmarM and our distinguished guests. pic.twitter.com/0bV1645Sg1
— Moderna (@moderna_tx) December 21, 2022
MODERNA FINALIZES STRATEGIC PARTNERSHIP WITH UK GOVERNMENT
https://investors.modernatx.com/news/news-details/2022/Moderna-Finalizes-Strategic-Partnership-with-UK-Government/default.aspx
BIG COMPANY ----- Moderna builds out upper management with new commercial SVP
https://www.bizjournals.com/boston/news/2022/12/20/chantal-friebertsh-user-svp-commercial-eur-me-ca.html?utm_source=sy&utm_medium=nsyp&utm_campaign=yh
Jefferies upgrades Moderna stock, raises price target 275 a share
https://finance.yahoo.com/video/jefferies-upgrades-moderna-stock-raises-204404764.html
THERMONUCLEAR BAD—Hospitals completely overwhelmed in China ever since restrictions dropped. Epidemiologist estimate
60% of & 10% of Earth’s population likely infected over next 90 days. Deaths likely in the millions—plural. This is just the start:
⚠️THERMONUCLEAR BAD—Hospitals completely overwhelmed in China ever since restrictions dropped. Epidemiologist estimate >60% of 🇨🇳 & 10% of Earth’s population likely infected over next 90 days. Deaths likely in the millions—plural. This is just the start—🧵pic.twitter.com/VAEvF0ALg9
— Eric Feigl-Ding (@DrEricDing) December 19, 2022
Personalized Medicine: The Future of Cancer Treatment is Not One-Size Fits All. Saturday, January 71:00 – 1:30 PM.
https://www.ces.tech/conference/55907/999722.aspx
Patients treated with a combination of mRNA-4157 plus Keytruda were 44% less likely to die or see their tumors return compared to patients who had Keytruda on its own. If these results can be repeated in a larger population, mRNA-4157 could become a new cancer drug in just a few years$$$$$$$$
Recent results suggest the company's cancer vaccine candidate can succeed where others have failed.
relax$
https://www.fool.com/investing/2022/12/15/is-moderna-a-good-stock-to-buy-right-now/
EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) RECOMMENDS THE USE OF MODERNA’S BA.1 TARGETING BIVALENT COVID-19 BOOSTER IN CHILDREN (6-11 YEARS) IN THE EUROPEAN UNION
https://investors.modernatx.com/news/news-details/2022/EMA-Committee-for-Medicinal-Products-for-Human-Use-CHMP-Recommends-the-Use-of-Modernas-BA.1-Targeting-Bivalent-COVID-19-Booster-in-Children-6-11-Years-In-the-European-Union/default.aspx
This is perhaps the first ever concrete recognition by wall street that Moderna is more than just a covid vaccine company. Next RSV and flu. Let's see what in store next for us$$$$$$$$$$
Why Moderna is expanding to Canada:
https://sponsorcontent.cnn.com/edition/2022/invest-in-canada/why-moderna-is-expanding/
People scared to get vaccinated by a company who just found the cure for cancer! LOL
The power of mRNA : Scientists have been studying mRNA for decades. And mRNA vaccines are just the start.
https://www.modernatx.com/power-of-mrna/science-of-mrna
$MRNA winner$$$$$$$$.
The vaccine and immunotherapy combination reportedly cleared the primary goal set by the researchers, with these patients experiencing significantly more time without their cancer returning on average than those who only received Keytruda (a metric known as recurrence-free survival).
Scientists have been greatly interested in personalized cancer vaccines for years, and this research has played a pivotal role in the development of mRNA vaccine technology, even before it was used as the base for covid-19 vaccines.
Many researchers have argued that combining these vaccines with immunotherapy drugs should further amplify their effect.
This will be be $1000+ stock in a few years. Short term I don’t care, long term very bullish.
huge news : Companies plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor types
$MRNA
Two Phase 3 studies and one registration enabled Phase 2 study with ARX788 (ACE-Breast-02, ACE-Gastric-02, and ACE-Breast-08) conducted by Amrbrx’s partner, NovoCodex Biopharmaceuticals, are ongoing in China with projected readouts in 2023.
The U.S. FDA has cleared an Investigational New Drug application by
Vertex Pharma
for VX-522, an mRNA therapy targeted at treating the underlying cause of CysticFibrosis, for people who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator.
VX-522 is the result of an exclusive research collaboration between Vertex and Moderna. VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle, and the mRNA is designed to produce functional copies of the CFTR protein.
https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-investigational-new-drug-ind-application-vx-522